« previous next »
Pages: [1]

Author Topic: (Abst.) Switching to Ocrevus in RRMS patients at risk of PML previously treated w/EID Tysabri  (Read 39 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9480
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Switching to Ocrevus in RRMS patients at risk of PML previously treated w/EID Tysabri
« on: August 07, 2020, 02:51:51 pm »
From PubMed (August 7, 2020)--"Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab":


https://pubmed.ncbi.nlm.nih.gov/32749910/
Report to moderator   Logged
MS Speaks--online for 16 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.
Pages: [1]
« previous next »
 

Related Topics

  Subject / Started by Replies Last post
0 Replies
133 Views 		Last post September 16, 2016, 11:36:28 am
by agate
0 Replies
96 Views 		Last post December 13, 2018, 09:02:08 pm
by agate
2 Replies
101 Views 		Last post October 17, 2019, 09:09:54 pm
by agate
1 Replies
40 Views 		Last post August 26, 2021, 06:56:59 pm
by agate
0 Replies
27 Views 		Last post October 16, 2021, 03:53:13 pm
by agate